title: Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study.
abstract: BACKGROUND
  Endoscopic and clinical recurrence of Crohn's disease (CD) appears in up to 80 and 30 % of patients, respectively, 1 year after surgery. Both infliximab (IFX) and adalimumab (ADA) have been demonstrated to be effective in reducing the possibility of recurrence after surgery, but head-to-head studies have not been performed so far. The aim of this open-label prospective study was to compare endoscopic, histological and clinical recurrence after 1 year of treatment with IFX or ADA as postoperative prophylaxis in CD patients with a high risk of recurrence.
  
  
  METHODS
  Consecutive CD patients who underwent curative ileocolonic resection were randomized to receive IFX or ADA for 1 year. Co-primary endpoints were endoscopic, histological and clinical recurrence after 12 months of therapy.
  
  
  RESULTS
  Twenty consecutive CD patients (9 males and 11 females; median age 32.5 years, range 20-39 years) were enrolled after undergoing curative ileocolonic resection. Among the 10 patients treated with IFX, 2 (20 %) had endoscopic recurrence compared to 1 (10 %) in the group of 10 ADA patients (p = 1.0). Three out of 10 (30 %) IFX patients and 2 out of 10 (20 %) ADA patients had histological recurrence (p = 1.0). No significant clinical differences were found between the two groups.
  
  
  CONCLUSIONS
  IFX and ADA were similar in preventing histological, endoscopic and clinical recurrence after curative ileocolonic resection in high risk CD patients.
authors.affiliation: Gastroenterology Service, ASL BAT, Via Torino, 49, 76123, Andria, BT, Italy, antotursi@tiscali.it.
authors.forename: A
authors.initials: A
authors.lastname: Tursi
authors.forename: W
authors.initials: W
authors.lastname: Elisei
authors.forename: M
authors.initials: M
authors.lastname: Picchio
authors.forename: C
authors.initials: C
authors.lastname: Zampaletta
authors.forename: G
authors.initials: G
authors.lastname: Pelecca
authors.forename: R
authors.initials: R
authors.lastname: Faggiani
authors.forename: G
authors.initials: G
authors.lastname: Brandimarte
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001706:Biopsy; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D013505:Digestive System Surgical Procedures; D004305:Dose-Response Relationship, Drug; D016145:Endoscopy, Digestive System; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D007279:Injections, Subcutaneous; D008297:Male; D010865:Pilot Projects; D011184:Postoperative Period; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab